Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
Year: 2025
Type: article
Source: Blood Neoplasia
Authors: Leah A. Goldberg, James J. Yoon, Hannah Johnston, Marta B. Davidson, Alexa Siddon, Rory M. Shallis, Evan C. Chen, Madelyn Burkart, Timothy S. Oh, Sunil G. Iyer, Ellen Madarang, Chandrasekar Muthiah, Joshua Kassner, Raajit K. Rampal, Guru Subramanian Guru Murthy, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Vikas Gupta, Kristen M. Pettit, Olatoyosi Odenike, John F. Cursio, Anand A. Patel
Institutions: University of Chicago Medical Center, Memorial Sloan Kettering Cancer Center, University of Chicago, Yale Cancer Center, Yale University, Dana-Farber Cancer Institute, Wake Forest Baptist Comprehensive Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, Medical College of Wisconsin, Cornell University, Weill Cornell Medicine, University of Michigan, Michigan Medicine
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4408196341